Cancer, Non-small Cell Lung Cancer (NSCLC)
Conditions
Keywords
Non-small Cell Lung Cancer (NCSLC), PTK7-Expressing Tumor, Antibody Drug Conjugate, cofetuzumab pelidotin, ABBV-647, Cancer
Brief summary
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Interventions
DRUGCofetuzumab Pelidotin
Intravenous (IV) infusion
Sponsors
AbbVie
Pfizer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed non-small cell lung cancer (NSCLC) with PTK7-expressing tumor using an immunohistochemistry (IHC) assay previously validated at a designated laboratory * Recurrent NSCLC that has progressed after treatment with at least the following approved therapies with demonstrated clinical benefit: a platinum-based chemotherapy doublet and an immune checkpoint inhibitor for tumors without targetable genetic alterations; a platinum-based chemotherapy doublet and targeted agent(s) for tumors with targeted genetic alterations * Received ≤ 2 prior lines of systemic therapy, including no more than 1 line of systemic cytotoxic chemotherapy (≤ 3 prior lines for tumors treated with targeted agent(s) for genetic alterations, including no more than 1 line of systemic chemotherapy) * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Adequate bone marrow, renal, and hepatic function per the protocol
Exclusion criteria
* Known uncontrolled metastases to the central nervous system (CNS). Participants with CNS metastases may be eligible provided that definitive therapy has been given, and participants are asymptomatic and off systemic steroids and anticonvulsants used for management of brain metastases for at least 2 weeks prior to the first dose of study drug * Unresolved clinically significant adverse events Grade ≥ 2 from prior anticancer therapy (with the exception of alopecia or anemia) * Has clinically significant medical condition(s) as described in the protocol * Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days prior to the first dose of study drug (no washout period required for participants on EGFR tyrosine kinase inhibitors). Palliative radiation therapy for bone, skin or subcutaneous metastases with 10 fractions or less is not subject to a washout period * Received anti-cancer herbal therapies within 7 days prior to the first dose of study drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) | Up to approximately 3 years | ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to approximately 3 years | OS is defined as the time from the participant's first dose of study drug until death from any cause. |
| Progression Free Survival (PFS) | Up to approximately 3 years | PFS is defined as the time from the participant's first dose of study drug until radiographic progression or death from any cause. |
| Duration of Response (DOR) | Up to approximately 3 years | DOR is defined as the time from the participant's initial response (CR or PR) to the first occurrence of radiographic progression or death from any cause. |
Countries
Israel, Japan, South Korea, Spain, Taiwan, United States
Contacts
STUDY_DIRECTORABBVIE INC.
AbbVie
Outcome results
None listed